GENMAB A/S |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2,003 DKK | -0.45% |
|
+1.91% | -7.05% |
| 05-03 | GENMAB : A good start to 2024; guidance unchanged |  |
| 05-03 | Genmab Posts Q1 Net Profit Surge; Revenue Jumps | MT |
ETFs positioned on Genmab A/S
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.04% | 0 M€ | +8.19% | - | |
| 0.04% | 284 M€ | -.--% | ||
| 0.03% | 0 M€ | +7.83% | - | |
| 0.03% | 0 M€ | +5.52% | - | |
| 0.03% | 0 M€ | +5.29% | - | |
| 0.02% | 0 M€ | +3.25% | - | |
| 0.02% | 0 M€ | +2.51% | - | |
| 0.01% | 0 M€ | +3.48% | - | |
| 0.01% | 0 M€ | +0.45% | - | |
| 0.01% | 0 M€ | +2.89% | - | |
| 0.01% | 0 M€ | +0.44% | - | |
| 0.00% | 0 M€ | 0.00% | - | |
| 0.00% | 0 M€ | -1.79% | - | |
| 0.00% | 0 M€ | -2.16% | - | |
| 0.00% | 0 M€ | -2.24% | - |
Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows:
- royalties (83.2%);
- income from research and development (12.4%);
- other (4.4%): primarily income from partnership agreement.
At the end of 2023, the group had a portfolio of more than 20 products in clinical development phase and 20 in preclinical development phase.
Denmark accounts for all net sales.
Calendar
2024-08-01
- Q2 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
A-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
22
Last Close Price
2,003
DKK
Average target price
2,470
DKK
Spread / Average Target
+23.31%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -7.05% | 18.64B | |
| +2.97% | 108B | |
| +10.21% | 105B | |
| +1.57% | 23.46B | |
| -12.77% | 21.72B | |
| -37.64% | 17.45B | |
| -6.50% | 17.19B | |
| +6.00% | 13.99B | |
| +37.20% | 12.53B | |
| +330.95% | 8.81B |
- Stock Market
- Equities
- GMAB Stock
- Funds and ETFs Genmab A/S